Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions.
Per Med
; 18(3): 233-240, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33728996
ABSTRACT
Aim:
We sought to explore how early adopters use pharmacogenomic (PGx) testing for treating depression and attention-deficit/hyperactivity disorder. Patients &methods:
Prescribers of the Informed PGx (Progenity, Inc., Ann Arbor, MI 48108, USA) test completed a phone survey assessing use of PGx testing for different scenarios. We conducted a qualitative thematic text analysis of transcribed audio recordings of open-ended responses (n = 62).Results:
PGx testing was used when treating multiple comorbidities or resistant disease, and to ease patients' concerns with future therapy. Use of PGx testing is influenced by insurance coverage, interpretability of results and results turnaround time.Conclusion:
Prescribers used PGx tests to modify medications for complex patients with depression, attention-deficit/hyperactivity disorder and other disorders to alleviate concerns related to adverse effects and lack of effectiveness.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Attention Deficit Disorder with Hyperactivity
/
Attitude of Health Personnel
/
Cytochrome P-450 Enzyme System
/
Depression
/
Pharmacogenomic Testing
Type of study:
Prognostic_studies
/
Qualitative_research
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Per Med
Year:
2021
Document type:
Article
Affiliation country:
Estados Unidos